SCHEMBL17111160

SCHEMBL17111160

COc1ccc(-c2cc(N)n(-c3ccccc3)n2)nn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 11/20 0.54
SMN1; SMN2 Q16637 11/20 0.54
NPC1 O15118 10/20 0.54
MAPT P10636 5/20 0.54
ALDH1A1 P00352 3/20 0.54
STAT1 P42224 1/20 0.54
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
TSHR P16473 2/20 0.52
GFER P55789 1/20 0.52
NFKB1 P19838 2/20 0.51
NFKB2 Q00653 2/20 0.51
RELA Q04206 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
KDM4E B2RXH2 2/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2C19 P33261 2/20 0.50
MAPK1 P28482 1/20 0.50
PTGS1 P23219 3/20 0.49
PTGS2 P35354 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11654832 0.80 CYP1A2 (0.61) RAB9ASMN1; SMN2NPC1MAPTALDH1A1
SCHEMBL1144023 0.75 RAB9A (0.71) RAB9ASMN1; SMN2NPC1MAPTALDH1A1
SCHEMBL537890 0.73 RAB9A (0.83) RAB9ASMN1; SMN2NPC1MAPTALDH1A1
SCHEMBL30229566 0.72 NPY5R (0.64) RAB9ASMN1; SMN2NPC1MAPTALDH1A1
SCHEMBL4048465 0.71 RAB9A (0.62) RAB9ASMN1; SMN2NPC1MAPTALDH1A1
SCHEMBL13860632 0.71 RAB9A (0.59) RAB9ASMN1; SMN2NPC1MAPTALDH1A1
SCHEMBL6981888 0.71 PDE10A (0.46) MAPTALDH1A1LMNAPOLB
SCHEMBL30229798 0.70 RAB9A (0.84) RAB9ASMN1; SMN2NPC1MAPTALDH1A1
SCHEMBL1143708 0.70 RAB9A (1.00) RAB9ASMN1; SMN2NPC1MAPTALDH1A1
SCHEMBL1456221 0.70 NNMT (0.46) RAB9ASMN1; SMN2NPC1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9914736-B2 TrKA kinase inhibitors, compositions and methods thereof MERCK SHARP & DOHME CORP. (US) 2018-03-13 US disclosed
US-20170158698-A1 TrKA Kinase Inhibitors, Compositions and Methods Thereof MERCK SHARP & DOHME CORP. (US) 2017-06-08 US disclosed
EP-3122343-A2 TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF Merck Sharp & Dohme Corp. (US) 2017-02-01 EP disclosed
WO-2015148350-A2 TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF MERCK SHARP & DOHME CORP. (US) 2015-10-01 WO disclosed
WO-2015143653-A1 TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF MERCK SHARP & DOHME CORP. (US) 2015-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170158698-A1 TrKA Kinase Inhibitors, Compositions and Methods Thereof NGFR, NGF, NTRK2 RAB9A 2490/4885SMN1; SMN2 2108/4885NPC1 1664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.